Andere Sprachen SpectraCure AB

Aktien

A2PD08

SE0007158118

SPEC

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:29:47 03.05.2024			% 5 Tage	% 1. Jan.
3,2 ^SEK	+8,47 %		+11,50 %	-17,10 %

23.02.	Spectracure AB (Publ) setzt den Prozess der Initiierung einer klinischen Studie für primär lokalisierten Prostatakrebs fort	CI
22.02.	SpectraCure AB (publ) meldet Ergebnis für das vierte Quartal und das Gesamtjahr bis zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

SpectraCure takes the next step in the work with the new clinical study	23.02.
Spectracure AB Continues in the Process of Initiating A Clinical Study, for Primary Localised Prostate Cancer	23.02.
SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	22.02.
A well-accomplished annual audit in accordance with ISO 13485:2016	23.01.
Expert group comments on results of ongoing study	19.12.
SpectraCure AB Conducts a Clinical Study for Patients with Recurrence of Prostate Cancer After Radiotherapy	19.12.
SpectraCure : Masoud Khayyami presents SpectraCure at investor meetingon November 5 in Lund!	29.11.
SpectraCure AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16.11.
SpectraCure has decided to seek approval for a clinical study of primary prostate cancer	16.11.
SpectraCure AB Decides to Seek Approval for Clinical Study of Primary Prostate Cancer	16.11.
SpectraCure : Meet SpectraCure’s board member, Homer Pien!	31.10.23
SpectraCure strengthens presence among urologists	06.10.23
SpectraCure AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17.08.23
SpectraCure has been awarded an additional EU grant for industrialisation of the company's treatment system Q-PRO®	27.06.23
SpectraCure Receives an Additional EU Grant	27.06.23
SpectraCure AB Reports Earnings Results for the First Quarter Ended March 31, 2023	16.05.23
SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	22.02.23
SpectraCures signs Letter of Intent with Cheplapharm	07.12.22
SpectraCures Signs Letter of Intent with Cheplapharm	07.12.22
SpectraCure : First treatment with Q-PRO and integrated image management technology	25.11.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen SpectraCure AB

Aktien

A2PD08

SE0007158118

SPEC

Andere Sprachen

Filter